Tags

Type your tag names separated by a space and hit enter

Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.
Mov Disord. 2018 03; 33(3):414-420.MD

Abstract

BACKGROUND

Caffeine intake has been inversely associated with Parkinson's disease (PD) risk. This relationship may be modified by polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2), but the results of previous studies have been inconsistent.

METHOD

We examined the interaction of caffeine intake with GRIN2A-rs4998386 and CYP1A2-rs762551 polymorphisms in influencing PD risk among 829 incident cases of PD and 2,754 matched controls selected among participants in the following 3 large prospective ongoing cohorts: the Nurses' Health Study, the Health Professionals' Follow-up Study, and the Cancer Prevention Study II Nutrition Cohort. Matching factors included cohort, birth year, source of DNA, date of DNA collection, and race. Relative risks and 95% confidence intervals were estimated using conditional logistic models. Interactions were tested both on the multiplicative scale and on the additive scale.

RESULTS

Overall, caffeine intake was associated with a lower PD risk (adjusted relative risk for highest versus lowest tertile = 0.70; 95% confidence interval, 0.57-0.86; p < .001). In analyses stratified by the GRIN2A-rs4998386 genotype, the multivariable-adjusted relative risk of PD comparing the highest to the lowest tertile of caffeine was 0.69 (95% confidence interval, 0.55-0.88; p < .01) among individuals homozygous for the C allele, and 0.85 (95% confidence interval, 0.55-1.32; p = .47; pRERI = .43) among carriers for the T allele. Interactions between caffeine and GRIN2A were not significant in either the multiplicative or additive scales. We also did not observe significant interactions for CYP1A2-rs762551 and incident PD risk.

CONCLUSION

Our findings do not support the hypothesis of an interaction between the GRIN2A-rs4998386 or CYP1A2-rs762551 polymorphism and caffeine intake in determining PD risk. © 2018 International Parkinson and Movement Disorder Society.

Authors+Show Affiliations

Department of Epidemiology, Harvard T. H. School Chan School of Public Health, Boston, Massachusetts, USA.Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. School of Public Health, University College Cork, Cork, Ireland.Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, Massachusetts, USA.Department of Epidemiology, Harvard T. H. School Chan School of Public Health, Boston, Massachusetts, USA. Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.The Institute for Aging Research, Hebrew Senior Life, Boston, Massachusetts, USA. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.Department of Epidemiology, Harvard T. H. School Chan School of Public Health, Boston, Massachusetts, USA. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

29318639

Citation

Kim, Iris Y., et al. "Interaction Between Caffeine and Polymorphisms of Glutamate Ionotropic Receptor NMDA Type Subunit 2A (GRIN2A) and Cytochrome P450 1A2 (CYP1A2) On Parkinson's Disease Risk." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 33, no. 3, 2018, pp. 414-420.
Kim IY, O'Reilly ÉJ, Hughes KC, et al. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Mov Disord. 2018;33(3):414-420.
Kim, I. Y., O'Reilly, É. J., Hughes, K. C., Gao, X., Schwarzschild, M. A., McCullough, M. L., Hannan, M. T., Betensky, R. A., & Ascherio, A. (2018). Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Movement Disorders : Official Journal of the Movement Disorder Society, 33(3), 414-420. https://doi.org/10.1002/mds.27279
Kim IY, et al. Interaction Between Caffeine and Polymorphisms of Glutamate Ionotropic Receptor NMDA Type Subunit 2A (GRIN2A) and Cytochrome P450 1A2 (CYP1A2) On Parkinson's Disease Risk. Mov Disord. 2018;33(3):414-420. PubMed PMID: 29318639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. AU - Kim,Iris Y, AU - O'Reilly,Éilis J, AU - Hughes,Katherine C, AU - Gao,Xiang, AU - Schwarzschild,Michael A, AU - McCullough,Marjorie L, AU - Hannan,Marian T, AU - Betensky,Rebecca A, AU - Ascherio,Alberto, Y1 - 2018/01/10/ PY - 2017/08/21/received PY - 2017/11/20/revised PY - 2017/11/26/accepted PY - 2018/1/11/pubmed PY - 2019/6/14/medline PY - 2018/1/11/entrez KW - CYP1A2 KW - GRIN2A KW - Parkinson's disease KW - caffeine KW - interaction SP - 414 EP - 420 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 33 IS - 3 N2 - BACKGROUND: Caffeine intake has been inversely associated with Parkinson's disease (PD) risk. This relationship may be modified by polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2), but the results of previous studies have been inconsistent. METHOD: We examined the interaction of caffeine intake with GRIN2A-rs4998386 and CYP1A2-rs762551 polymorphisms in influencing PD risk among 829 incident cases of PD and 2,754 matched controls selected among participants in the following 3 large prospective ongoing cohorts: the Nurses' Health Study, the Health Professionals' Follow-up Study, and the Cancer Prevention Study II Nutrition Cohort. Matching factors included cohort, birth year, source of DNA, date of DNA collection, and race. Relative risks and 95% confidence intervals were estimated using conditional logistic models. Interactions were tested both on the multiplicative scale and on the additive scale. RESULTS: Overall, caffeine intake was associated with a lower PD risk (adjusted relative risk for highest versus lowest tertile = 0.70; 95% confidence interval, 0.57-0.86; p < .001). In analyses stratified by the GRIN2A-rs4998386 genotype, the multivariable-adjusted relative risk of PD comparing the highest to the lowest tertile of caffeine was 0.69 (95% confidence interval, 0.55-0.88; p < .01) among individuals homozygous for the C allele, and 0.85 (95% confidence interval, 0.55-1.32; p = .47; pRERI = .43) among carriers for the T allele. Interactions between caffeine and GRIN2A were not significant in either the multiplicative or additive scales. We also did not observe significant interactions for CYP1A2-rs762551 and incident PD risk. CONCLUSION: Our findings do not support the hypothesis of an interaction between the GRIN2A-rs4998386 or CYP1A2-rs762551 polymorphism and caffeine intake in determining PD risk. © 2018 International Parkinson and Movement Disorder Society. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/29318639/Interaction_between_caffeine_and_polymorphisms_of_glutamate_ionotropic_receptor_NMDA_type_subunit_2A__GRIN2A__and_cytochrome_P450_1A2__CYP1A2__on_Parkinson's_disease_risk_ L2 - https://doi.org/10.1002/mds.27279 DB - PRIME DP - Unbound Medicine ER -